Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage

J. K V Willson, P. H. Fischer, K. Tutsch, D. Alberti, K. Simon, R. D. Hamilton, J. Bruggink, J. M. Koeller, D. C. Tormey, R. H. Earhart, A. Ranhosky, D. L. Trump

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

A Phase I clinical trial of simultaneous 72-h infusions of dipyridamole and acivicin was carried out in patients with advanced malignancies. The objective of this trial was to determine the maximum tolerated dose of dipyridamole when administered as a 72-h infusion in combination with acivicin. The development of this combination is of interest because of in vitro observations which demonstrate that dipyridamole potentiates the cytotoxic action of acivicin by blocking nucleoside salvage. Patients were treated with concomitant i.v. infusions of dipyridamole and acivicin for 72 h. The acivicin dose infused remained constant during the trial at 60 mg/m2/72 h. The maximum tolerated dose (MTD) of dipyridamole was 23.1 mg/kg/72 h. Limiting toxicities at the MTD of dipyridamole with acivicin were severe gastrointestinal and constitutional symptoms which appeared to be caused by the high doses of dipyridamole administered. Escalation of dipyridamole did not potentiate the mild myelosuppression or the neurotoxicity which occurs with acivicin alone. At a dose of dipyridamole which was well below the MTD, one patient experienced symptomatic orthostatic hypotension, and another patient with coronary artery disease developed dizziness and transient electrocardiogram abnormalities. However, no other hypotensive or cardiovascular events occurred as dipyridamole was escalated to the MTD. Phlebitis occurred at the site of infusion when the dose of dipyridamole exceeded 13.5 mg/kg/72 h. Because of this local toxicity, it was necessary to administer dipyridamole through a central venous catheter to achieve maximum plasma levels. At the MTD of dipyridamole, steady-state total and free plasma levels of 11.9 μM and 27.8 nM, respectively, were attained by 24 h. These are free dipyridamole levels which in vitro were sufficient to block cytidine salvage and to potentiate the biochemical and cytotoxic effects of acivicin against human colon cancer cells.

Original languageEnglish (US)
Pages (from-to)5585-5590
Number of pages6
JournalCancer Research
Volume48
Issue number19
StatePublished - 1988

Fingerprint

acivicin
Clinical Trials, Phase I
Dipyridamole
Nucleosides
Maximum Tolerated Dose

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Willson, J. K. V., Fischer, P. H., Tutsch, K., Alberti, D., Simon, K., Hamilton, R. D., ... Trump, D. L. (1988). Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage. Cancer Research, 48(19), 5585-5590.

Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage. / Willson, J. K V; Fischer, P. H.; Tutsch, K.; Alberti, D.; Simon, K.; Hamilton, R. D.; Bruggink, J.; Koeller, J. M.; Tormey, D. C.; Earhart, R. H.; Ranhosky, A.; Trump, D. L.

In: Cancer Research, Vol. 48, No. 19, 1988, p. 5585-5590.

Research output: Contribution to journalArticle

Willson, JKV, Fischer, PH, Tutsch, K, Alberti, D, Simon, K, Hamilton, RD, Bruggink, J, Koeller, JM, Tormey, DC, Earhart, RH, Ranhosky, A & Trump, DL 1988, 'Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage', Cancer Research, vol. 48, no. 19, pp. 5585-5590.
Willson JKV, Fischer PH, Tutsch K, Alberti D, Simon K, Hamilton RD et al. Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage. Cancer Research. 1988;48(19):5585-5590.
Willson, J. K V ; Fischer, P. H. ; Tutsch, K. ; Alberti, D. ; Simon, K. ; Hamilton, R. D. ; Bruggink, J. ; Koeller, J. M. ; Tormey, D. C. ; Earhart, R. H. ; Ranhosky, A. ; Trump, D. L. / Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage. In: Cancer Research. 1988 ; Vol. 48, No. 19. pp. 5585-5590.
@article{6345bf8671e647d7bc70f41dc086af1a,
title = "Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage",
abstract = "A Phase I clinical trial of simultaneous 72-h infusions of dipyridamole and acivicin was carried out in patients with advanced malignancies. The objective of this trial was to determine the maximum tolerated dose of dipyridamole when administered as a 72-h infusion in combination with acivicin. The development of this combination is of interest because of in vitro observations which demonstrate that dipyridamole potentiates the cytotoxic action of acivicin by blocking nucleoside salvage. Patients were treated with concomitant i.v. infusions of dipyridamole and acivicin for 72 h. The acivicin dose infused remained constant during the trial at 60 mg/m2/72 h. The maximum tolerated dose (MTD) of dipyridamole was 23.1 mg/kg/72 h. Limiting toxicities at the MTD of dipyridamole with acivicin were severe gastrointestinal and constitutional symptoms which appeared to be caused by the high doses of dipyridamole administered. Escalation of dipyridamole did not potentiate the mild myelosuppression or the neurotoxicity which occurs with acivicin alone. At a dose of dipyridamole which was well below the MTD, one patient experienced symptomatic orthostatic hypotension, and another patient with coronary artery disease developed dizziness and transient electrocardiogram abnormalities. However, no other hypotensive or cardiovascular events occurred as dipyridamole was escalated to the MTD. Phlebitis occurred at the site of infusion when the dose of dipyridamole exceeded 13.5 mg/kg/72 h. Because of this local toxicity, it was necessary to administer dipyridamole through a central venous catheter to achieve maximum plasma levels. At the MTD of dipyridamole, steady-state total and free plasma levels of 11.9 μM and 27.8 nM, respectively, were attained by 24 h. These are free dipyridamole levels which in vitro were sufficient to block cytidine salvage and to potentiate the biochemical and cytotoxic effects of acivicin against human colon cancer cells.",
author = "Willson, {J. K V} and Fischer, {P. H.} and K. Tutsch and D. Alberti and K. Simon and Hamilton, {R. D.} and J. Bruggink and Koeller, {J. M.} and Tormey, {D. C.} and Earhart, {R. H.} and A. Ranhosky and Trump, {D. L.}",
year = "1988",
language = "English (US)",
volume = "48",
pages = "5585--5590",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage

AU - Willson, J. K V

AU - Fischer, P. H.

AU - Tutsch, K.

AU - Alberti, D.

AU - Simon, K.

AU - Hamilton, R. D.

AU - Bruggink, J.

AU - Koeller, J. M.

AU - Tormey, D. C.

AU - Earhart, R. H.

AU - Ranhosky, A.

AU - Trump, D. L.

PY - 1988

Y1 - 1988

N2 - A Phase I clinical trial of simultaneous 72-h infusions of dipyridamole and acivicin was carried out in patients with advanced malignancies. The objective of this trial was to determine the maximum tolerated dose of dipyridamole when administered as a 72-h infusion in combination with acivicin. The development of this combination is of interest because of in vitro observations which demonstrate that dipyridamole potentiates the cytotoxic action of acivicin by blocking nucleoside salvage. Patients were treated with concomitant i.v. infusions of dipyridamole and acivicin for 72 h. The acivicin dose infused remained constant during the trial at 60 mg/m2/72 h. The maximum tolerated dose (MTD) of dipyridamole was 23.1 mg/kg/72 h. Limiting toxicities at the MTD of dipyridamole with acivicin were severe gastrointestinal and constitutional symptoms which appeared to be caused by the high doses of dipyridamole administered. Escalation of dipyridamole did not potentiate the mild myelosuppression or the neurotoxicity which occurs with acivicin alone. At a dose of dipyridamole which was well below the MTD, one patient experienced symptomatic orthostatic hypotension, and another patient with coronary artery disease developed dizziness and transient electrocardiogram abnormalities. However, no other hypotensive or cardiovascular events occurred as dipyridamole was escalated to the MTD. Phlebitis occurred at the site of infusion when the dose of dipyridamole exceeded 13.5 mg/kg/72 h. Because of this local toxicity, it was necessary to administer dipyridamole through a central venous catheter to achieve maximum plasma levels. At the MTD of dipyridamole, steady-state total and free plasma levels of 11.9 μM and 27.8 nM, respectively, were attained by 24 h. These are free dipyridamole levels which in vitro were sufficient to block cytidine salvage and to potentiate the biochemical and cytotoxic effects of acivicin against human colon cancer cells.

AB - A Phase I clinical trial of simultaneous 72-h infusions of dipyridamole and acivicin was carried out in patients with advanced malignancies. The objective of this trial was to determine the maximum tolerated dose of dipyridamole when administered as a 72-h infusion in combination with acivicin. The development of this combination is of interest because of in vitro observations which demonstrate that dipyridamole potentiates the cytotoxic action of acivicin by blocking nucleoside salvage. Patients were treated with concomitant i.v. infusions of dipyridamole and acivicin for 72 h. The acivicin dose infused remained constant during the trial at 60 mg/m2/72 h. The maximum tolerated dose (MTD) of dipyridamole was 23.1 mg/kg/72 h. Limiting toxicities at the MTD of dipyridamole with acivicin were severe gastrointestinal and constitutional symptoms which appeared to be caused by the high doses of dipyridamole administered. Escalation of dipyridamole did not potentiate the mild myelosuppression or the neurotoxicity which occurs with acivicin alone. At a dose of dipyridamole which was well below the MTD, one patient experienced symptomatic orthostatic hypotension, and another patient with coronary artery disease developed dizziness and transient electrocardiogram abnormalities. However, no other hypotensive or cardiovascular events occurred as dipyridamole was escalated to the MTD. Phlebitis occurred at the site of infusion when the dose of dipyridamole exceeded 13.5 mg/kg/72 h. Because of this local toxicity, it was necessary to administer dipyridamole through a central venous catheter to achieve maximum plasma levels. At the MTD of dipyridamole, steady-state total and free plasma levels of 11.9 μM and 27.8 nM, respectively, were attained by 24 h. These are free dipyridamole levels which in vitro were sufficient to block cytidine salvage and to potentiate the biochemical and cytotoxic effects of acivicin against human colon cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=0023685838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023685838&partnerID=8YFLogxK

M3 - Article

VL - 48

SP - 5585

EP - 5590

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 19

ER -